Comparative Pharmacology
Head-to-head clinical analysis: SPECTAZOLE versus VFEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPECTAZOLE versus VFEND.
SPECTAZOLE vs VFEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
Inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
IV: Loading dose of 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. Oral: Weight ≥40 kg: Loading dose of 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours; weight <40 kg: Loading dose of 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Terminal half-life is approximately 24 hours (range 12–30 h) in adults. Prolonged in hepatic impairment (Child-Pugh A: 48 h; B: 72 h).
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Primarily hepatic metabolism; <2% excreted unchanged in urine. Fecal excretion accounts for ~80% of metabolites. Renal excretion of unchanged drug is negligible.
Category C
Category C
Antifungal
Antifungal